Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apellis Pharmaceuticals Inc.

www.apellis.com

Latest From Apellis Pharmaceuticals Inc.

Finance Watch: Two New IPOs – IGM In the US, Henlius In Hong Kong – Gross Nearly $600m

Public Company Edition: IGM raised $175m to advance its IgM antibodies and Henlius brought in $410m for its novel drug and biosimilar platforms. Also, Acadia follow-on brings in $250m, PTC sells $350m worth of stock and debt, and Karyopharm royalty deal totals $150m.

Financing Business Strategies

Gyroscope Merger Creates Gene Therapy Biotech For Eye Disorders

A new UK/US biotech tie-up makes a company with the technology to deliver its gene therapies.
M & A Ophthalmic

Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish

Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.

Deals Financing

Ionis Catches The Eye With New Roche Alliance

October has been a very good month for Ionis. Following US approval of Tegredi, it has now signed a potentially lucrative deal with existing partner Roche for another antisense drug, this time to tackle advanced dry AMD.

Ophthalmic Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Immune Disorders
  • Ophthalmic
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Apellis Pharmaceuticals Inc.
  • Senior Management
  • Cedric Francois, MD, PhD, Pres. & CEO
    Timothy Sullivan, CFO
    Pascal Deschatelets, PhD, COO
    David Watson, VP, Corp. Dev.
    Federico Grossi, CMO
  • Contact Info
  • Apellis Pharmaceuticals Inc.
    Phone: (502) 241-4114
    6400 Westwind Way
    Ste. A
    Crestwood, KY 40014
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register